Cellnovo Group (“Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, today provides an update on progress towards the buildup to full-scale manufacturing of its mobile, connected, all-in-one diabetes management system by Flex.
Following the delivery of the first pilot batch of insulin cartridges announced in September, Cellnovo and Flex have achieved two additional milestones.
First, a ramp up of the wax actuator assembly production at the Flex facility that will result in a 50% capacity increase at Cellnovo’s South Wales manufacturing facility in Q1 2017. Secondly, further improvements have been made to the Flex manufacturing processes to increase the yield and quality of the full insulin cartridge.
Full commercial production of the insulin cartridges is expected for early Q2 2017. The capacity of the Flex production line in Austria (Althofen) will be fully scalable, with potential to meet customer demand, in line with 2017 expectations.